Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $11 Price Target
Needham重申對Recursion Pharmaceuticals的買入評級，維持11美元的目標股價
Needham analyst Gil Blum reiterates Recursion Pharmaceuticals (NASDAQ:RXRX) with a Buy and maintains $11 price target.
Needham分析師Gil Blum重申對回歸製藥（納斯達克:RXRX）的買入評級，維持11美元的目標價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。